林业发展局提议批准使用时间长的防晒霜成分Bemotrizinol,供美国在2026年底使用,扩大广泛的保护选择。 The FDA proposes approving bemotrizinol, a long-used sunscreen ingredient, for U.S. use by late 2026, expanding broad-spectrum protection options.

林业发展局提议允许Bemotrizinol(欧洲和澳大利亚20多年来使用的防晒剂成分)进入美国产品中,这是25年多来首次批准新的化学紫外线过滤器。 The FDA is proposing to allow bemotrizinol, a sunscreen ingredient used for over two decades in Europe and Australia, into U.S. products, marking the first new chemical UV filter approval in more than 25 years. 在2020年《CARES法》的推动下,该举措旨在扩大广泛频谱保护,防止UVA和UVB射线,拟议的浓度限制为6%,用于6个月及6个月以上的成人和儿童。 The move, driven by the 2020 CARES Act, aims to expand access to broad-spectrum protection against UVA and UVB rays, with a proposed concentration limit of 6% for use in adults and children six months and older. Bemotrizinol以阳光稳定、皮肤低刺激和鲜少吸收进入血液而闻名。 Bemotrizinol is known for stability in sunlight, low skin irritation, and minimal absorption into the bloodstream. 美国食品和药物管理局将在2026年初之前最终决定,并邀请公众发表意见. The FDA has until early 2026 to finalize its decision, with public comment invited. 如果获得批准,它可以在2026年底在美国的防晒霜上出现,使规章现代化,并使其更符合全球标准。 If approved, it could appear in U.S. sunscreens by late 2026, modernizing regulations and aligning them more closely with global standards.